Sidon

WAYFIND-R is a global registry focused on collecting high-quality real-world data from cancer patients diagnosed with solid tumors who have undergone next-generation sequencing (NGS) testing. The registry aims to support clinical and epidemiological research, generate evidence to better understand health outcomes and cancer care, and describe treatments and clinical courses for these patients. Participants must be adults diagnosed with any type of solid tumor at any disease stage and have had NGS testing within three months before enrollment. The study collects data without assigning specific treatments or interventions, instead tracking clinical characteristics and outcomes over time. During the study, researchers will gather information linking NGS results to treatments and patient outcomes, including overall survival for up to five years from enrollment. Participants provide informed consent, and data collected will help improve understanding of solid tumor cancers and their management in real-world settings.

Researchers are evaluating whether a home-based program combining laughter and fun yoga can reduce pain in children aged 2 to 10 years who have acute lymphoblastic leukemia and are receiving chemotherapy with dexamethasone. This randomized, multicenter clinical trial aims to see if adding these gentle, playful activities to usual care lowers pain, reduces the need for strong pain medicines like opioids, and improves mood, anxiety, and sleep during treatment. Participants are randomly assigned to either the laughter and fun yoga group or the usual care group. The intervention group completes a structured program at home over six consecutive days that includes guided video sessions with gentle yoga movements, breathing exercises, laughter activities, guided play, and positive affirmations. Parents or caregivers actively participate and supervise these low-intensity activities. The control group receives standard pain management care without the added laughter and yoga program. During the six-day study period after chemotherapy, children’s pain is measured daily using a child-friendly pain scale. Parents answer brief questions about pain medicine use, mood, anxiety, and sleep. The study collects data to determine if the intervention helps reduce pain intensity and improve overall well-being. All participants continue their regular medical care throughout the study, which is designed to be safe and non-invasive.